Global Plasma-derived Therapies Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Description

According to our latest research, the global Plasma-derived Therapies market size will reach USD million in 2029, growing at a CAGR of % over the analysis period.

Plasma-derived therapeutics start from human blood plasma instead of the chemical or synthetic materials from which most pharmaceuticals are made.

The Plasma-derived Therapies market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

Market segmentation
Plasma-derived Therapies market is split by Type and by Application. For the period 2023-2029, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
    Albumin
    Immunoglobulin
    Factor VIII
    Others

Market segment by Application, can be divided into
    Hemophilia
    Primary Immunodeficiencies (PIDs)
    Idiopathic Thrombocytopenic Purpura (ITP)
    COVID-19
    Others

Market segment by players, this report covers
    CSL Behring LLC
    Shire
    Bayer
    Kedrion
    Takeda
    Biotest
    Octaparma
    Bio Products Laboratory (BPL)
    LFB
    Grifols

Market segment by regions, regional analysis covers
    North America
    Europe
    Asia-Pacific (China, Japan, South Korea, Rest of Asia-Pacific)
    South America
    Middle East & Africa

The content of the study subjects, includes a total of 8 chapters:
Chapter 1, to describe Plasma-derived Therapies product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Plasma-derived Therapies, with recent developments and future plans
Chapter 3, the Plasma-derived Therapies competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4, to break the market size data at the region level, with key companies in the key region and Plasma-derived Therapies market forecast, by regions, with revenue, from 2023 to 2029.
Chapter 5 and 6, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2023 to 2029.
Chapter 7 and 8, to describe Plasma-derived Therapies research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Plasma-derived Therapies
    1.2 Classification of Plasma-derived Therapies by Type
        1.2.1 Overview: Global Plasma-derived Therapies Market Size by Type: 2022 Versus 2028
        1.2.2 Global Plasma-derived Therapies Revenue Market Share by Type in 2029
        1.2.3 Albumin
        1.2.4 Immunoglobulin
        1.2.5 Factor VIII
        1.2.6 Others
    1.3 Global Plasma-derived Therapies Market by Application
        1.3.1 Overview: Global Plasma-derived Therapies Market Size by Application: 2023 Versus 2029
        1.3.2 Hemophilia
        1.3.3 Primary Immunodeficiencies (PIDs)
        1.3.4 Idiopathic Thrombocytopenic Purpura (ITP)
        1.3.5 COVID-19
        1.3.6 Others
    1.4 Global Plasma-derived Therapies Market Size & Forecast
    1.5 Market Drivers, Restraints and Trends
        1.5.1 Plasma-derived Therapies Market Drivers
        1.5.2 Plasma-derived Therapies Market Restraints
        1.5.3 Plasma-derived Therapies Trends Analysis

2 Company Profiles
    2.1 CSL Behring LLC
        2.1.1 CSL Behring LLC Details
        2.1.2 CSL Behring LLC Major Business
        2.1.3 CSL Behring LLC Plasma-derived Therapies Product and Solutions
        2.1.4 CSL Behring LLC Recent Developments and Future Plans
    2.2 Shire
        2.2.1 Shire Details
        2.2.2 Shire Major Business
        2.2.3 Shire Plasma-derived Therapies Product and Solutions
        2.2.4 Shire Recent Developments and Future Plans
    2.3 Bayer
        2.3.1 Bayer Details
        2.3.2 Bayer Major Business
        2.3.3 Bayer Plasma-derived Therapies Product and Solutions
        2.3.4 Bayer Recent Developments and Future Plans
    2.4 Kedrion
        2.4.1 Kedrion Details
        2.4.2 Kedrion Major Business
        2.4.3 Kedrion Plasma-derived Therapies Product and Solutions
        2.4.4 Kedrion Recent Developments and Future Plans
    2.5 Takeda
        2.5.1 Takeda Details
        2.5.2 Takeda Major Business
        2.5.3 Takeda Plasma-derived Therapies Product and Solutions
        2.5.4 Takeda Recent Developments and Future Plans
    2.6 Biotest
        2.6.1 Biotest Details
        2.6.2 Biotest Major Business
        2.6.3 Biotest Plasma-derived Therapies Product and Solutions
        2.6.4 Biotest Recent Developments and Future Plans
    2.7 Octaparma
        2.7.1 Octaparma Details
        2.7.2 Octaparma Major Business
        2.7.3 Octaparma Plasma-derived Therapies Product and Solutions
        2.7.4 Octaparma Recent Developments and Future Plans
    2.8 Bio Products Laboratory (BPL)
        2.8.1 Bio Products Laboratory (BPL) Details
        2.8.2 Bio Products Laboratory (BPL) Major Business
        2.8.3 Bio Products Laboratory (BPL) Plasma-derived Therapies Product and Solutions
        2.8.4 Bio Products Laboratory (BPL) Recent Developments and Future Plans
    2.9 LFB
        2.9.1 LFB Details
        2.9.2 LFB Major Business
        2.9.3 LFB Plasma-derived Therapies Product and Solutions
        2.9.4 LFB Recent Developments and Future Plans
    2.10 Grifols
        2.10.1 Grifols Details
        2.10.2 Grifols Major Business
        2.10.3 Grifols Plasma-derived Therapies Product and Solutions
        2.10.4 Grifols Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Plasma-derived Therapies Revenue and Share by Players (2023 & 2029)
    3.2 Plasma-derived Therapies Players Head Office, Products and Services Provided
    3.3 Plasma-derived Therapies Mergers & Acquisitions
    3.4 Plasma-derived Therapies New Entrants and Expansion Plans

4 Global Plasma-derived Therapies Forecast by Region
    4.1 Global Plasma-derived Therapies Market Size by Region: 2023 VS 2029
    4.2 Global Plasma-derived Therapies Market Size by Region, (2023-2029)
    4.3 North America
        4.3.1 Key Companies of Plasma-derived Therapies in North America
        4.3.2 Current Situation and Forecast of Plasma-derived Therapies in North America
        4.3.3 North America Plasma-derived Therapies Market Size and Prospect (2023-2029)
    4.4 Europe
        4.4.1 Key Companies of Plasma-derived Therapies in Europe
        4.4.2 Current Situation and Forecast of Plasma-derived Therapies in Europe
        4.4.3 Europe Plasma-derived Therapies Market Size and Prospect (2023-2029)
    4.5 Asia-Pacific
        4.5.1 Key Companies of Plasma-derived Therapies in Asia-Pacific
        4.5.2 Current Situation and Forecast of Plasma-derived Therapies in Asia-Pacific
        4.5.3 Asia-Pacific Plasma-derived Therapies Market Size and Prospect (2023-2029)
        4.5.4 China
        4.5.5 Japan
        4.5.6 South Korea
    4.6 South America
        4.6.1 Key Companies of Plasma-derived Therapies in South America
        4.6.2 Current Situation and Forecast of Plasma-derived Therapies in South America
        4.6.3 South America Plasma-derived Therapies Market Size and Prospect (2023-2029)
    4.7 Middle East & Africa
        4.7.1 Key Companies of Plasma-derived Therapies in Middle East & Africa
        4.7.2 Current Situation and Forecast of Plasma-derived Therapies in Middle East & Africa
        4.7.3 Middle East & Africa Plasma-derived Therapies Market Size and Prospect (2023-2029)

5 Market Size Segment by Type
    5.1 Global Plasma-derived Therapies Market Forecast by Type (2023-2029)
    5.2 Global Plasma-derived Therapies Market Share Forecast by Type (2023-2029)

6 Market Size Segment by Application
    6.1 Global Plasma-derived Therapies Market Forecast by Application (2023-2029)
    6.2 Global Plasma-derived Therapies Market Share Forecast by Application (2023-2029)

7 Research Findings and Conclusion

8 Appendix
    8.1 Methodology
    8.2 Research Process and Data Source
    8.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Plasma-derived Therapies Revenue by Type, (USD Million), 2023 VS 2029
    Table 2. Global Plasma-derived Therapies Revenue by Application, (USD Million), 2023 VS 2029
    Table 3. CSL Behring LLC Corporate Information, Head Office, and Major Competitors
    Table 4. CSL Behring LLC Major Business
    Table 5. CSL Behring LLC Plasma-derived Therapies Product and Solutions
    Table 6. Shire Corporate Information, Head Office, and Major Competitors
    Table 7. Shire Major Business
    Table 8. Shire Plasma-derived Therapies Product and Solutions
    Table 9. Bayer Corporate Information, Head Office, and Major Competitors
    Table 10. Bayer Major Business
    Table 11. Bayer Plasma-derived Therapies Product and Solutions
    Table 12. Kedrion Corporate Information, Head Office, and Major Competitors
    Table 13. Kedrion Major Business
    Table 14. Kedrion Plasma-derived Therapies Product and Solutions
    Table 15. Takeda Corporate Information, Head Office, and Major Competitors
    Table 16. Takeda Major Business
    Table 17. Takeda Plasma-derived Therapies Product and Solutions
    Table 18. Biotest Corporate Information, Head Office, and Major Competitors
    Table 19. Biotest Major Business
    Table 20. Biotest Plasma-derived Therapies Product and Solutions
    Table 21. Octaparma Corporate Information, Head Office, and Major Competitors
    Table 22. Octaparma Major Business
    Table 23. Octaparma Plasma-derived Therapies Product and Solutions
    Table 24. Bio Products Laboratory (BPL) Corporate Information, Head Office, and Major Competitors
    Table 25. Bio Products Laboratory (BPL) Major Business
    Table 26. Bio Products Laboratory (BPL) Plasma-derived Therapies Product and Solutions
    Table 27. LFB Corporate Information, Head Office, and Major Competitors
    Table 28. LFB Major Business
    Table 29. LFB Plasma-derived Therapies Product and Solutions
    Table 30. Grifols Corporate Information, Head Office, and Major Competitors
    Table 31. Grifols Major Business
    Table 32. Grifols Plasma-derived Therapies Product and Solutions
    Table 33. Global Plasma-derived Therapies Revenue (USD Million) by Players (2023 & 2029)
    Table 34. Global Plasma-derived Therapies Revenue Share by Players (2023 & 2029)
    Table 35. Plasma-derived Therapies Players Head Office, Products and Services Provided
    Table 36. Plasma-derived Therapies Mergers & Acquisitions in the Past Five Years
    Table 37. Plasma-derived Therapies New Entrants and Expansion Plans
    Table 38. Global Market Plasma-derived Therapies Revenue (USD Million) Comparison by Region (2023 VS 2029)
    Table 39. Global Plasma-derived Therapies Revenue Market Share by Region (2023-2029)
    Table 40. Key Companies of Plasma-derived Therapies in North America
    Table 41. Current Situation and Forecast of Plasma-derived Therapies in North America
    Table 42. Key Companies of Plasma-derived Therapies in Europe
    Table 43. Current Situation and Forecast of Plasma-derived Therapies in Europe
    Table 44. Key Companies of Plasma-derived Therapies in Asia-Pacific
    Table 45. Current Situation and Forecast of Plasma-derived Therapies in Asia-Pacific
    Table 46. Key Companies of Plasma-derived Therapies in China
    Table 47. Key Companies of Plasma-derived Therapies in Japan
    Table 48. Key Companies of Plasma-derived Therapies in South Korea
    Table 49. Key Companies of Plasma-derived Therapies in South America
    Table 50. Current Situation and Forecast of Plasma-derived Therapies in South America
    Table 51. Key Companies of Plasma-derived Therapies in Middle East & Africa
    Table 52. Current Situation and Forecast of Plasma-derived Therapies in Middle East & Africa
    Table 53. Global Plasma-derived Therapies Revenue Forecast by Type (2023-2029)
    Table 54. Global Plasma-derived Therapies Revenue Forecast by Application (2023-2029)
List of Figures
    Figure 1. Plasma-derived Therapies Picture
    Figure 2. Global Plasma-derived Therapies Revenue Market Share by Type in 2029
    Figure 3. Albumin
    Figure 4. Immunoglobulin
    Figure 5. Factor VIII
    Figure 6. Others
    Figure 7. Plasma-derived Therapies Revenue Market Share by Application in 2029
    Figure 8. Hemophilia Picture
    Figure 9. Primary Immunodeficiencies (PIDs) Picture
    Figure 10. Idiopathic Thrombocytopenic Purpura (ITP) Picture
    Figure 11. COVID-19 Picture
    Figure 12. Others Picture
    Figure 13. Global Plasma-derived Therapies Market Size, (USD Million): 2023 VS 2029
    Figure 14. Global Plasma-derived Therapies Revenue and Forecast (2023-2029) & (USD Million)
    Figure 15. Plasma-derived Therapies Market Drivers
    Figure 16. Plasma-derived Therapies Market Restraints
    Figure 17. Plasma-derived Therapies Market Trends
    Figure 18. CSL Behring LLC Recent Developments and Future Plans
    Figure 19. Shire Recent Developments and Future Plans
    Figure 20. Bayer Recent Developments and Future Plans
    Figure 21. Kedrion Recent Developments and Future Plans
    Figure 22. Takeda Recent Developments and Future Plans
    Figure 23. Biotest Recent Developments and Future Plans
    Figure 24. Octaparma Recent Developments and Future Plans
    Figure 25. Bio Products Laboratory (BPL) Recent Developments and Future Plans
    Figure 26. LFB Recent Developments and Future Plans
    Figure 27. Grifols Recent Developments and Future Plans
    Figure 28. Global Plasma-derived Therapies Revenue Market Share by Region (2023-2029)
    Figure 29. Global Plasma-derived Therapies Revenue Market Share by Region in 2029
    Figure 30. North America Plasma-derived Therapies Revenue (USD Million) and Growth Rate (2023-2029)
    Figure 31. Europe Plasma-derived Therapies Revenue (USD Million) and Growth Rate (2023-2029)
    Figure 32. Asia-Pacific Plasma-derived Therapies Revenue (USD Million) and Growth Rate (2023-2029)
    Figure 33. South America Plasma-derived Therapies Revenue (USD Million) and Growth Rate (2023-2029)
    Figure 34. Middle East & Africa Plasma-derived Therapies Revenue (USD Million) and Growth Rate (2023-2029)
    Figure 35. Global Plasma-derived Therapies Market Share Forecast by Type (2023-2029)
    Figure 36. Global Plasma-derived Therapies Market Share Forecast by Application (2023-2029)
    Figure 37. Methodology
    Figure 38. Research Process and Data Source

Companies Mentioned

CSL Behring LLC
Shire
Bayer
Kedrion
Takeda
Biotest
Octaparma
Bio Products Laboratory (BPL)
LFB
Grifols